KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

被引：27

作者：

Hoimes, Christopher J.

Bedke, Jens

Loriot, Yohann

Nishiyama, Hiroyuki

Fang, Xiao

Kataria, Ritesh S.

Moreno, Blanca Homet

Galsky, Matt D.

机构：

[1] Duke Univ, Durham, NC USA

[2] Eberhard Karls Univ Tubingen, Tubingen, Germany

[3] Gustave Roussy, Canc Campus, Villejuif, France

[4] Univ Tsukuba, Ibaraki, Japan

[5] Merck & Co Inc, Kenilworth, NJ USA

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS4587

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4587

引用

页数：3